Vaccina Patria advances and is in the final stage of clinical development: Conacyt – ContraRéplica

Clinical development of the Patria vaccine against Covid-19 continues to advance, the National Council of Science and Technology (CONACYT) reported.

It was also reported, at the request of President Andrés Manuel López Obrador, that the vaccine is in its final stage. The Mexican-made vaccine will be applied to more than three thousand volunteers and the call for participation in the recruitment of volunteers is still in force.

President Andrés Manuel López Obrador said María Elena Álvarez-Buylla, head of Conacyt, would present a report on the Mexican vaccine. This statement came after NotiPress questioned the president during the December 14, 2022 press conference on vaccine development.

It was through a press release issued the same day by the National Council of Science and Technology (Conacyt) in which the joint work carried out with the Avi-Mex laboratory, SA de CV and the technology promoted by the government of Mexico was reported. Similarly, Conacyt recalled, the registration of the results of the final phase of clinical development is expected in the first half of 2023, to advance towards emergency authorization.

The statement indicates “a safe development capable of producing a protective response against the SARS-CoV-2 virus as a reinforcement, until now”. Approximately 3,860 volunteers will be vaccinated at eleven sites distributed in Mexico City, Oaxaca, Mérida, Morelia, Mexico State and Acapulco.

To be part of the volunteers who will receive the Patria vaccine, registration is open on the patria.conacyt.mxse page. Where you can also check the requirements to apply for the application.

With information from NotiPress

Image: darkroom